146 related articles for article (PubMed ID: 34954620)
41. Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.
McCreary EK; Nguyen MH; Davis MR; Borlagdan J; Shields RK; Anderson AD; Rivosecchi RM; Marini RV; Sacha LM; Silveira FP; Andes DR; Lepak AJ
J Antimicrob Chemother; 2020 Oct; 75(10):3023-3028. PubMed ID: 32710097
[TBL] [Abstract][Full Text] [Related]
42. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous alternariosis in a cardiac transplant recipient.
Gilmour TK; Rytina E; O'Connell PB; Sterling JC
Australas J Dermatol; 2001 Feb; 42(1):46-9. PubMed ID: 11233722
[TBL] [Abstract][Full Text] [Related]
44. Subcutaneous phaeohyphomycosis due to Alternaria infectoria in a renal transplant patient: surgical treatment with no long-term relapse.
Salido-Vallejo R; Linares-Sicilia MJ; Garnacho-Saucedo G; Sánchez-Frías M; Solís-Cuesta F; Gené J; Moreno-Giménez JC
Rev Iberoam Micol; 2014; 31(2):149-51. PubMed ID: 22771424
[TBL] [Abstract][Full Text] [Related]
45. [Cutaneous alternariosis. Clinical diagnosis and therapeutic options].
Mayser P; Thoma W; Seibold M; Tintelnot K; Wiedemeyer K; de Hoog GS
Hautarzt; 2004 Dec; 55(12):1137-42. PubMed ID: 15448927
[TBL] [Abstract][Full Text] [Related]
46. Alternaria infectoria skin infection in a renal transplant recipient: an emerging phaeohyphomycosis of occidental countries?
Aragón-Miguel R; Calleja-Algarra A; Morales-Raya C; López-Medrano F; Pérez-Ayala A; Rodríguez-Peralto JL; Ortiz-Romero PL; Maroñas-Jiménez L
Int J Dermatol; 2017 Jul; 56(7):e153-e155. PubMed ID: 28244068
[No Abstract] [Full Text] [Related]
47. In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.
Buil JB; Brüggemann RJM; Bedin Denardi L; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2020 Sep; 75(9):2582-2586. PubMed ID: 32516368
[TBL] [Abstract][Full Text] [Related]
48. Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.
Mendoza MA; Anderson A; Morris MI; Lekakis L; Simkins J; Prado CE; Martinez OV; Komanduri KV; Camargo JF
Mycopathologia; 2020 Apr; 185(2):399-403. PubMed ID: 31925638
[TBL] [Abstract][Full Text] [Related]
49. Alternaria alternata invasive fungal infection in a patient with Fanconi's anemia after an unrelated bone marrow transplant.
Ferreira Ide S; Teixeira G; Abecasis M
Clin Drug Investig; 2013 Feb; 33 Suppl 1():S33-6. PubMed ID: 23381982
[TBL] [Abstract][Full Text] [Related]
50. Isavuconazonium sulfate for the treatment of fungal infection.
Walker RC; Zeuli JD; Temesgen Z
Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
[TBL] [Abstract][Full Text] [Related]
51. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre.
Bowen CD; Tallman GB; Hakki M; Lewis Ⅱ JS
Mycoses; 2019 Aug; 62(8):665-672. PubMed ID: 31050373
[TBL] [Abstract][Full Text] [Related]
52. Disseminated lomentosporiosis in a heart transplant recipient: Case report and review of the literature.
Valerio M; Vásquez V; Álvarez-Uria A; Zatarain-Nicolás E; Pavone P; Martínez-Jiménez MDC; Barrio-Gutiérrez JM; Cuerpo G; Guinea-Ortega J; Vena A; Peligros-Gómez MI; Bouza E; Muñoz P
Transpl Infect Dis; 2021 Aug; 23(4):e13574. PubMed ID: 33527651
[TBL] [Abstract][Full Text] [Related]
53. Sporotrichoid phaeohyphomycosis due to Alternaria infectoria.
Gerdsen R; Uerlich M; De Hoog GS; Bieber T; Horré R
Br J Dermatol; 2001 Sep; 145(3):484-6. PubMed ID: 11531842
[TBL] [Abstract][Full Text] [Related]
54. Phaeohyphomycosis caused by Alternaria infectoria presenting as multiple vegetating lesions in a renal transplant patient.
Cunha D; Amaro C; Vieira MR; Martins Mda L; Maduro AP; Inácio J; Afonso A; Pinto GM; Cardoso J
Rev Iberoam Micol; 2012; 29(1):44-6. PubMed ID: 21787876
[TBL] [Abstract][Full Text] [Related]
55. Graded isavuconazole introduction in a patient with voriconazole allergy.
Morales MK; Harris C; Shoham S
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28851131
[TBL] [Abstract][Full Text] [Related]
56. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN; Carver PL
Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
[TBL] [Abstract][Full Text] [Related]
57. Real-world use-Isavuconazole at a large academic medical center.
Hassouna H; Athans V; Brizendine KD
Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
[TBL] [Abstract][Full Text] [Related]
58. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
Livermore J; Hope W
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
[TBL] [Abstract][Full Text] [Related]
60. Isavuconazole shortens the QTc interval.
Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
